These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 23201823)

  • 1. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer.
    Kubasiak JC; Seder CW; Pithadia R; Basu S; Fhied C; Phillips WW; Daly S; Shersher DD; Yoder MA; Chmielewski G; Edell ES; Maldonado F; Liptay MJ; Borgia JA
    J Thorac Cardiovasc Surg; 2015 Mar; 149(3):727-34.e1-3; discussion 734. PubMed ID: 25312225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.
    Seder CW; Kubasiak JC; Pithadia R; Basu S; Fhied C; Tarhoni I; Davila E; Alnajjar H; Chmielewski GW; Warren WH; Liptay MJ; Borgia JA
    Ann Thorac Surg; 2015 Aug; 100(2):429-36. PubMed ID: 26138771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of Combined Detection of Cytokines and Tumor Markers in the 
Differential Diagnosis of Benign and Malignant Solitary Pulmonary Nodules].
    Shi J; Liu X; Ming Z; Li W; Lv X; Yang X; Wang Y; Zhang M; Yang S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):426-433. PubMed ID: 34157802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
    Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography in the diagnostic work-up of screening-detected lung nodules.
    Veronesi G; Travaini LL; Maisonneuve P; Rampinelli C; Bertolotti R; Spaggiari L; Bellomi M; Paganelli G
    Eur Respir J; 2015 Feb; 45(2):501-10. PubMed ID: 25261326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer.
    Borgia JA; Basu S; Faber LP; Kim AW; Coon JS; Kaiser-Walters KA; Fhied C; Thomas S; Rouhi O; Warren WH; Bonomi P; Liptay MJ
    J Thorac Oncol; 2009 Mar; 4(3):338-47. PubMed ID: 19190517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.
    Xing L; Su J; Guarnera MA; Zhang H; Cai L; Zhou R; Stass SA; Jiang F
    Clin Cancer Res; 2015 Jan; 21(2):484-9. PubMed ID: 25593345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Malignancy Risk of Screen-Detected Lung Nodules-Mean Diameter or Volume.
    Tammemagi M; Ritchie AJ; Atkar-Khattra S; Dougherty B; Sanghera C; Mayo JR; Yuan R; Manos D; McWilliams AM; Schmidt H; Gingras M; Pasian S; Stewart L; Tsai S; Seely JM; Burrowes P; Bhatia R; Haider EA; Boylan C; Jacobs C; van Ginneken B; Tsao MS; Lam S;
    J Thorac Oncol; 2019 Feb; 14(2):203-211. PubMed ID: 30368011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment and Verification of A Novel Predictive Model of Malignancy
for Non-solid Pulmonary Nodules].
    Xiao F; Yu Q; Zhang Z; Liu D; Liang C
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):26-33. PubMed ID: 30674390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
    Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
    Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
    Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
    Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination.
    Gierada DS; Pinsky P; Nath H; Chiles C; Duan F; Aberle DR
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25326638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a multiprotein plasma classifier to identify benign lung nodules.
    Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
    J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.